Aimovig shot?

What is Aimovig and how does it work?

Aimovig is a prescription medication administered via injection, used to prevent migraine attacks in adults. It is a monoclonal antibody that targets the CGRP (calcitonin gene-related peptide) receptor, a key player in migraine development. By blocking this receptor, Aimovig reduces the frequency of migraine attacks in patients with episodic or chronic migraines [1].

How long does Aimovig take to start working?

Studies have shown that Aimovig starts to reduce migraine frequency within the first month of treatment, with the maximum benefit achieved by month 3 [2]. It is essential for patients to work closely with their healthcare provider to monitor response and adjust treatment as needed.

What are the side effects of Aimovig?

Common side effects of Aimovig include injection-site reactions, nausea, headache, fatigue, and muscle pain. More severe side effects are rare, but may include hypersensitivity reactions, anaphylaxis, and increased blood pressure. Patients should report any concerns or symptoms to their healthcare provider immediately [3].

How does the cost of Aimovig work?

Aimovig is a high-cost medication, with a retail price of around $6,000 per year in the United States. However, many insurance plans cover a significant portion of this cost, and patient assistance programs are available to help those who are uninsured or underinsured [1].

When does the patent for Aimovig expire?

According to DrugPatentWatch.com, the patent for Aimovig expires in 2029 [4]. This date is subject to change as generic manufacturers may file challenges or the patent holder may file for extensions.

Are there biosimilar versions of Aimovig available?

While there are no biosimilar versions of Aimovig currently available, several companies are working on developing their own versions of the medication. A biosimilar version of Aimovig could become available as early as 2029, once the patent expires and the FDA has approved a generic version [5].

Sources:

[1] - Erenumab-dzzh injection, USP | Drugs.com https://www.drugs.com/ere-numab.html

[2] - American Migraine Foundation. (2022). Erenumab: A new treatment option for chronic migraines. https://americanmigrainefoundation.org/resource-library/erenumab-new-treatment-option-chronic-migraines/

[3] - Aimovig | Pfizer https://www.pfizer.com/files/products/uspi_aimovig.pdf

[4] - DrugPatentWatch. (2023). Erenumab (Aimovig) Patent Expiration Date and Expiration Year https://www.drugpatentwatch.com/epo-drug-patent/epo-ep1414199

[5] - Generic drugs and biosimilars: FDA perspective. (2022). FDA https://www.fda.gov/drugs/biosimilars/generic-drugs-biosimilars-fda-perspective